Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)
Authors:
- 10 March 2006
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 21 (3) , 169-175
Abstract
No specific characteristics have been identified as predictors of peripheral blood stem cells (PBSC) mobilization in healthy donors. In this study, clinical characteristics and laboratory data for 122 healthy donors who underwent apheresis on day 5 of treatment with recombinant granulocyte colony-stimulating factor (G-CSF) were retrospectively analyzed for correlations with CD34+ cell mobilization. The variables that were analyzed included age, sex, body weight, basal complete blood count, and maximum white blood count (WBC) before apheresis, G-CSF type, and dosage. Median age and body weight were 42.5 years (range 16–65) and 72.5 kg (range 47–121), respectively. By univariate analysis, male sex (P = 0.007), body weight (≤ 70 vs. >70 kg, P = 0.04), and donor's age (≤ 50 vs. > 50 years; P = 0.015) were correlated with the number of CD34+ cells mobilized. By multivariate analysis, donor's age and male sex were the only two variables that significantly predicted a high CD34+ cell level. In conclusion, our data suggest that male sex and younger age are the only factors that significantly affect CD34+ mobilization in healthy donors. J Clin Apheresis.Keywords
This publication has 30 references indexed in Scilit:
- Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donorsBone Marrow Transplantation, 2002
- Dose and Schedule Effect of G-GSF for Stem Cell Mobilization in Healthy Donors for Allogeneic TransplantationLeukemia & Lymphoma, 2002
- Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating studyBone Marrow Transplantation, 2000
- Blood and marrow transplantation activity in Europe 1997Bone Marrow Transplantation, 1999
- High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ ImmunoselectionJournal of Clinical Oncology, 1999
- Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantationBone Marrow Transplantation, 1998
- Stem Cell Mobilization in Normal DonorsJournal of Hematotherapy, 1997
- Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastimTransfusion, 1997
- Large Volume Leukapheresis Maximizes the Progenitor Cell Yield for Allogeneic Peripheral Blood Progenitor DonationJournal of Hematotherapy, 1997
- Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the proceduresTransfusion, 1996